These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 15717942)

  • 1. Clinical experience with monoclonal antibodies to epidermal growth factor receptor.
    Calvo E; Rowinsky EK
    Curr Oncol Rep; 2005 Mar; 7(2):96-103. PubMed ID: 15717942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer.
    López-Albaitero A; Ferris RL
    Arch Otolaryngol Head Neck Surg; 2007 Dec; 133(12):1277-81. PubMed ID: 18086972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
    Snyder LC; Astsaturov I; Weiner LM
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
    Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.
    Capdevila J; Elez E; Macarulla T; Ramos FJ; Ruiz-Echarri M; Tabernero J
    Cancer Treat Rev; 2009 Jun; 35(4):354-63. PubMed ID: 19269105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
    Martinelli E; De Palma R; Orditura M; De Vita F; Ciardiello F
    Clin Exp Immunol; 2009 Oct; 158(1):1-9. PubMed ID: 19737224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
    Zhang W; Gordon M; Lenz HJ
    Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR-targeting monoclonal antibodies in head and neck cancer.
    Astsaturov I; Cohen RB; Harari PM
    Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New trends in epidermal growth factor receptor-directed monoclonal antibodies.
    Markman B; Capdevila J; Elez E; Tabernero J
    Immunotherapy; 2009 Nov; 1(6):965-82. PubMed ID: 20635913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
    Gridelli C; Maione P; Ferrara ML; Rossi A
    Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor.
    Alvarenga ML; Kikhney J; Hannewald J; Metzger AU; Steffens KJ; Bomke J; Krah A; Wegener A
    Anal Biochem; 2012 Feb; 421(1):138-51. PubMed ID: 22085444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
    Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
    Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
    Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG
    Crit Rev Oncol Hematol; 2001 Apr; 38(1):17-23. PubMed ID: 11255078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of an anti-epidermal growth factor receptor in treating cancer.
    Waksal HW
    Cancer Metastasis Rev; 1999; 18(4):427-36. PubMed ID: 10855786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.
    Zhu Z
    Acta Pharmacol Sin; 2007 Sep; 28(9):1476-93. PubMed ID: 17723181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab: from bench to bedside.
    Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
    Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
    Cohenuram M; Saif MW
    Anticancer Drugs; 2007 Jan; 18(1):7-15. PubMed ID: 17159497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.